| Literature DB >> 25810530 |
Elizabeth Hammond1, Jordan Lang1, Yoshiko Maeda1, David Pleasure2, Melinda Angus-Hill3, Jie Xu1, Makoto Horiuchi4, Wenbin Deng5, Fuzheng Guo6.
Abstract
Genetic or pharmacological activation of canonical Wnt/β-catenin signaling inhibits oligodendrocyte differentiation. Transcription factor 7-like 2 (TCF7l2), also known as TCF4, is a Wnt effector induced transiently in the oligodendroglial lineage. A well accepted dogma is that TCF7l2 inhibits oligodendrocyte differentiation through activation of Wnt/β-catenin signaling. We report that TCF7l2 is upregulated transiently in postmitotic, newly differentiated oligodendrocytes. Using in vivo gene conditional ablation, we found surprisingly that TCF7l2 positively regulates neonatal and postnatal mouse oligodendrocyte differentiation during developmental myelination and remyelination in a manner independent of the Wnt/β-catenin signaling pathway. We also reveal a novel role of TCF7l2 in repressing a bone morphogenetic protein signaling pathway that is known to inhibit oligodendrocyte differentiation. Thus, our study provides novel data justifying therapeutic attempts to enhance, rather than inhibit, TCF7l2 signaling to overcome arrested oligodendroglial differentiation in multiple sclerosis and other demyelinating diseases.Entities:
Keywords: BMP signaling; TCF7l2(TCF4); canonical Wnt/beta-catenin signaling; myelination; oligodendrocyte differentiation; remyelination
Mesh:
Substances:
Year: 2015 PMID: 25810530 PMCID: PMC6705374 DOI: 10.1523/JNEUROSCI.4787-14.2015
Source DB: PubMed Journal: J Neurosci ISSN: 0270-6474 Impact factor: 6.167